# BOSTON SCIENTIFIC CORP (BSX) — merger/definitive [pending]
Source: SEC API (secapi.ai) · situation sit_8b0c82e48bbd1d8a40d7 · retrieved 2026-08-12T21:20:40.074Z

## Overview
Boston Scientific Corporation is a medical device company that develops and markets surgical and medical instruments and apparatus, including interventional cardiology, vascular, neuromodulation, and endoscopy products.

Boston Scientific Corporation announced its acquisition of Penumbra Inc., a medical device company specializing in neurovascular and thrombectomy solutions. The transaction combines two strong companies with complementary portfolios; Penumbra will operate as a stand-alone business unit under Boston Scientific's cardiovascular group, retaining its commercial team and global business unit president. Boston Scientific expects to leverage its international scale and customer relationships to expand Penumbra's presence outside the United States, while Penumbra's neurovascular and thrombectomy capabilities complement Boston Scientific's interventional cardiology and vascular portfolio. The companies are currently working through regulatory approvals, with closing timing dependent on receipt of required regulatory clearances.

## Terms
- Counterparty: Penumbra Inc. · Deal value: $14.50B · Consideration: mixed · Premium: 19.0% · Price/share: $374

## Key dates
- Announced 2026-01-15 · Expected close 2026-12-31

## Timeline
- 2026-01-15 · 425 (0000947871-26-000035): 425 - BOSTON SCIENTIFIC CORP — *Penumbra, Inc. is the world's leading thrombectomy company focused on developing innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism, and acute limb ischemia, with a broad portfolio including computer-assisted vacuum thrombectomy (CAVT) systems and peripheral embolization products.* Boston Scientific Corporation agreed to acquire Penumbra, Inc. in a cash-and-stock transaction announced January 15, 2026. The transaction values Penumbra at $374 per share, reflecting an enterprise value of approximately $14.5 billion. Penumbra stockholders may elect to receive $374 in cash or 3.8721 shares of Boston Scientific common stock (valued at $374 based on the 10-day volume-weighted average price as of January 13, 2026), subject to proration, resulting in approximately 73% cash and 27% stock consideration. Boston Scientific expects to finance the approximately $11 billion cash portion with a combination of cash on hand and new debt. The transaction is expected to close in 2026, subject to Penumbra stockholder approval and customary closing conditions.
  https://www.sec.gov/Archives/edgar/data/885725/0000947871-26-000035.txt
- 2026-01-15 · 425 (0000947871-26-000039): 425 - BOSTON SCIENTIFIC CORP — *Penumbra Inc. develops and commercializes novel minimally invasive medical technologies for mechanical thrombectomy and neurovascular interventions, with products available in over 100 global markets and preliminary full-year 2025 revenue of $1.4 billion.* Boston Scientific Corporation entered into an agreement to acquire Penumbra Inc. for $374 per Penumbra common share in cash and stock for a total consideration of $15 billion. The transaction will be funded with approximately $11 billion in cash (73%) and $4 billion in Boston Scientific stock (27%), resulting in an equity issuance of approximately 41 million shares fixed at signing based on Boston Scientific's 10-day VWAP ending January 13, 2026. The acquisition is expected to close in 2026, subject to customary closing conditions, with potential closing in the first half of 2026 but more likely the second half. Upon close, Penumbra CEO Adam Elsesser will join Boston Scientific's Board of Directors.
  https://www.sec.gov/Archives/edgar/data/885725/0000947871-26-000039.txt
- 2026-01-15 · 425 (0000947871-26-000038): 425 - BOSTON SCIENTIFIC CORP — *Penumbra, Inc. is a medical device company that develops and commercializes minimally invasive interventional medical devices for neurovascular and peripheral vascular disease.* Boston Scientific Corporation entered into a definitive merger agreement on January 14, 2026 to acquire Penumbra, Inc. for mixed consideration. Each Penumbra share will convert into either $374.00 in cash or 3.8721 Boston Scientific shares, at the election of the holder, subject to proration such that 73.26% of shares receive cash and 26.74% receive stock. Based on Penumbra's 39,229,670 outstanding shares as of January 12, 2026, the transaction is valued at approximately $14.7 billion in aggregate consideration (39,229,670 shares × $374 = $14.67 billion on a cash basis). Penumbra will survive as a wholly owned subsidiary of Boston Scientific. The transaction is subject to customary closing conditions including Penumbra stockholder approval, regulatory clearances including HSR approval, and the absence of material adverse effects.
  https://www.sec.gov/Archives/edgar/data/885725/0000947871-26-000038.txt
- 2026-01-15 · 425 (0000947871-26-000040): 425 - BOSTON SCIENTIFIC CORP — *Penumbra Inc develops mechanical thrombectomy and neurovascular therapy devices to treat conditions including pulmonary embolism, stroke, deep vein thrombosis, acute limb ischemia, heart attack and aneurysms.* Boston Scientific Corporation announced a definitive agreement to acquire Penumbra, Inc., a leading innovator in mechanical thrombectomy and neurovascular therapies. Penumbra's comprehensive portfolio includes differentiated devices to treat conditions such as pulmonary embolism, stroke, deep vein thrombosis, acute limb ischemia, heart attack and aneurysms. The acquisition offers Boston Scientific an opportunity to enter new, fast-growing segments within the vascular space.
  https://www.sec.gov/Archives/edgar/data/885725/0000947871-26-000040.txt
- 2026-01-20 · 425 (0000947871-26-000060): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation is a medical device company that develops and markets cardiovascular, neurovascular, and other medical devices; it is expanding its Minnesota footprint and seeking to re-enter the neurovascular market.* Boston Scientific Corporation entered into a definitive agreement to acquire Penumbra, Inc. for $14.5 billion in an all-cash and stock transaction. The deal comprises 73% cash and 27% stock consideration. Boston Scientific expects the transaction to close sometime in 2026. The acquisition adds neurovascular devices to Boston Scientific's cardiovascular portfolio, providing products that treat stroke-causing blood clots in the brain and pulmonary embolism clots in the lungs. Penumbra expects 2025 revenue of roughly $1.4 billion, growing by more than 17% compared with 2024.
  https://www.sec.gov/Archives/edgar/data/885725/0000947871-26-000060.txt
- 2026-01-20 · 425 (0000947871-26-000059): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation is a medtech company that develops and markets cardiovascular, neurovascular, and other medical devices; it has a significant Minnesota presence and has completed approximately 50 acquisitions over the past 14 years.* Boston Scientific Corporation entered into a definitive agreement to acquire Penumbra, Inc. for $14.5 billion in an all-cash and stock transaction. The deal, announced on January 15, 2026, is structured as 73% cash and 27% stock. Boston Scientific expects the acquisition to close sometime in 2026. The transaction adds neurovascular devices to Boston Scientific's cardiovascular portfolio, providing access to treatments for stroke-causing blood clots in the brain and pulmonary embolism clots in the lungs. Penumbra expects 2025 revenue of roughly $1.4 billion, growing by more than 17% compared with 2024.
  https://www.sec.gov/Archives/edgar/data/885725/0000947871-26-000059.txt
- 2026-02-04 · 425 (0000947871-26-000086): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation develops and manufactures medical devices for cardiovascular, neuromodulation, urology, and other surgical and medical applications.* Boston Scientific Corporation announced an agreement to acquire Penumbra Inc., a medical device company offering differentiated products in mechanical thrombectomy and neurovascular segments where Boston Scientific currently lacks offerings. The transaction is expected to close in 2026, subject to customary closing conditions and regulatory approvals. Boston Scientific characterized the deal as both strategically and financially attractive, delivering significant value to patients and customers globally.
  https://www.sec.gov/Archives/edgar/data/885725/0000947871-26-000086.txt
- 2026-03-03 · 425 (0001104659-26-022918): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation is a medical device company that develops and markets surgical and medical instruments and apparatus, including interventional cardiology, vascular, neuromodulation, and endoscopy products.* Boston Scientific Corporation announced its acquisition of Penumbra Inc., a medical device company specializing in neurovascular and thrombectomy solutions. The transaction combines two strong companies with complementary portfolios; Penumbra will operate as a stand-alone business unit under Boston Scientific's cardiovascular group, retaining its commercial team and global business unit president. Boston Scientific expects to leverage its international scale and customer relationships to expand Penumbra's presence outside the United States, while Penumbra's neurovascular and thrombectomy capabilities complement Boston Scientific's interventional cardiology and vascular portfolio. The companies are currently working through regulatory approvals, with closing timing dependent on receipt of required regulatory clearances.
  https://www.sec.gov/Archives/edgar/data/885725/0001104659-26-022918.txt

## Citations
- 0000947871-26-000035 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000094787126000035
- 0000947871-26-000039 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000094787126000039
- 0000947871-26-000038 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000094787126000038
- 0000947871-26-000040 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000094787126000040
- 0000947871-26-000060 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000094787126000060
- 0000947871-26-000059 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000094787126000059
- 0000947871-26-000086 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000094787126000086
- 0001104659-26-022918 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465926022918